Identification and exploration of herb-drug combinations used by cancer patients

Integrative Cancer Therapies

Volumn 8, Issue 1, 2009, Pages 29-36

  Engdal, Silje ^a,c   Klepp, Olbjørn ^b   Nilsen, Odd Georg ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Alesund Hospital   (Norway)

^c Medical Technical Research Center Trondheim   (Norway)

Author keywords

Chemotherapy; Cytochrome P 450; Herb drug interactions; Medicinal herbs; P glycoprotein

Indexed keywords

AGARICUS BLAZEI EXTRACT; ALKYLATING AGENT; ALOE VERA EXTRACT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ECHINACEA EXTRACT; ETOPOSIDE; GARLIC EXTRACT; GINGER EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; MONOCLONAL ANTIBODY; MORINDA CITRIFOLIA EXTRACT; NAVELBINE; NITROSOUREA; PACLITAXEL; PLATINUM DERIVATIVE; PODOPHYLLOTOXIN DERIVATIVE; PYRIMIDINE DERIVATIVE; RHODIOLA ROSEA EXTRACT; TAXANE DERIVATIVE; UNINDEXED DRUG; VALERIAN; VINCA ALKALOID; VINCRISTINE; VISCUM ALBUM EXTRACT;

ADULT; AGARICUS BLAZEI; AGED; ALOE VERA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ECHINACEA; ENZYME METABOLISM; FEMALE; GARLIC; GINGER; GINKGO BILOBA; GINSENG; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; MORINDA CITRIFOLIA; PRIORITY JOURNAL; PROTEIN TRANSPORT; RHODIOLA; TEA; UNSPECIFIED SIDE EFFECT; VALERIANA OFFICINALIS; VISCUM ALBUM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DATA COLLECTION; DATABASES, FACTUAL; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 61849148341     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735408330202     Document Type: Article

References (46)

1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998 ; 280: 1569-1575.
2. Boon HS, Olatunde F., Zick SM Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 2007 ; 7: 4.
3. Hall SD, Wang Z., Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 ; 74: 525-535.
4. Bauer S., Stormer E., Johne A., et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol. 2003 ; 55: 203-211.
5. Singh SR, Levine MAH. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol. 2007 ; 47: 249-258.
6. Bush TM, Rayburn KS, Holloway SW, et al. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med. 2007 ; 13: 30-35.
7. Elmer GW, Lafferty WE, Tyree PT, Lind BK Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother. 2007 ; 41: 1617-1624.
8. Malekzadeh F., Rose C., Ingvar C., Jernstrom H. Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter. Studie kartlägger bruk av medel som kanske motverkar behandlingen. Lakartidningen. 2005 ; 102: 3226-3231.
9. Eschiti VS Lesson from comparison of CAM use by women with female-specific cancers to others: It's time to focus on interaction risks with CAM therapies. Integr Cancer Ther. 2007 ; 6: 313-344.
10. Engdal S., Steinsbekk A., Klepp O., Nilsen OG Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer. 2008 ; 16: 763-769.
11. World Health Organization. National Policy on Traditional Medicine and Regulation of Herbal Medicines - Report of a WHO Global Survey. Geneva, Switzerland: World Health Organization ; 2005.
12. Netsch MI, Gutmann H., Schmidlin CB, Aydogan C., Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med. 2006 ; 72: 514-520.
13. Yang SP, Raner GM Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. Toxicol Appl Pharmacol. 2005 ; 202: 140-150.
14. Muto S., Fujita KI, Yamazaki Y., Kamataki T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res. 2001 ; 479: 197-206.
15. Wang E. - J. Barecki - Roach M., Johnson WW Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun. 2002 ; 297: 412-418.
16. Foster BC, Foster MS, Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001 ; 4: 176-184.
17. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr. 2006 ; 136: 806S - 809S.
18. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med. 2005 ; 11: 433-439.
19. Modarai M., Gertsch J., Suter A., Heinrich M., Kortenkamp A. Cytochrome P450 inhibitory action of echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol. 2007 ; 59: 567-573.
20. Hellum BH, Nilsen OG In vitro inhibition of CYP3A4 metabolism and P-glycoprotein mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. In press.
21. Budzinski JW, Foster BC, Trudeau VL, Drouin CE, Bafi-Yeboa N., Arnason JT The interaction of selected phytochemicals, HIV drugs, and commercial-source herbal teas and capsules with human cytochrome P450 3A4 and P-glycoprotein. Pharm Biol. 2008 ; 46: 53-65.
22. Lefebvre T., Foster BC, Drouin CE, Krantis A., Livesey JF, Jordan SA In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci. 2004 ; 7: 265-273.
23. Hellum BH, Hu Z., Nilsen OG The induction of CYP1A2, CYP2D6, and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007 ; 100: 23-30.
24. Hellum BH, Nilsen OG In vitro inhibition of CYP3A4 metabolism and P-glycoprotein mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008 ; 102: 466-475.
25. Anderson GD, Rosito G., Mohustsy MA, Elmer GW Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003 ; 43: 643-648.
26. Foster BC, Vandenhoek S., Hana J., et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine. 2003 ; 10: 334-342.
27. Li Y., Mezei O., Shay NF Human and murine hepatic sterol-12-alpha- hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones. J Nutr. 2007 ; 137: 1705-1712.
28. Green AK, Barnes DM, Karasov WH A new method to measure intestinal activity of P-glycoprotein in avian and mammalian species. J Comp Physiol [B]. 2005 ; 175: 57-66.
29. Brandin H., Viitanen E., Myrberg O., Arvidsson AK Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4, and MDR1 in the human colon carcinoma cell line LS180. Phytother Res. 2007 ; 21: 239-244.
30. Raucy JL Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 2003 ; 31: 533-539.
31. Scott IM, Leduc RI, Burt AJ, Marles RJ, Arnason JT, Foster BC The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals. Pharm Biol. 2006 ; 44: 315-327.
32. Engdal S., Nilsen OG Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica. 2008 ; 36: 559-573.
33. Matsuda K., Nishimura Y., Kurata N., Iwase M., Yasuhara H. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. J Pharmacol Sci. 2007 ; 103: 214-221.
34. Cox MC, Low J., Lee J., et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res. 2006 ; 12: 4636-4640.
35. Chow HH, Hakim IA, Vining DR, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006 ; 15: 2473-2476.
36. Donovan JL, Chavin KD, Devane CL, et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos. 2004 ; 32: 906-908.
37. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005 ; 77: 415-426.
38. Donovan JL, DeVane CL, Chavin KD, et al. Multiple nighttime doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004 ; 32: 1333-1336.
39. Piscitelli SC, Burstein AH, Welden N., Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002 ; 34: 234-238.
40. Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y., Donovan JL Effects of garlic (Allium sativum L) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther. 2003 ; 74: 170-177.
41. Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng, and Ginkgo biloba. Drugs Aging. 2005 ; 22: 525-539.
42. Gorski JC, Huang SM, Pinto A., et al. The effect of echinacea (echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004 ; 75: 89-100.
43. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004 ; 76: 428-440.
44. Balayssac D., Authier N., Cayre A., Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions ? Toxicol Lett. 2005 ; 156: 319-329.
45. Scripture CD, Sparreboom A., Figg WD Modulation of cytochrome P450 activity: Implications for cancer therapy. Lancet Oncol. 2005 ; 6: 780-789.
46. Kleeberg UR, Suciu S., Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomized phase III trial. rIFNalpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004 ; 40: 390-402.